Novo NordiskView company profile and Eli LillyView company profile presented early data at the ARDD conference suggesting semaglutideView drug details and tirzepatideView drug details may slow molecular measures of biological aging.
Novo reported proteomic clock differences of roughly two to three years, with up to four years on a clock tracking heart proteins, in a 10,052-person study.
Lilly's epigenetic sub-study within SURMOUNT-5 found all 15 age-unit clocks showed less aging than the 1.38 years of elapsed chronological time.
Novo NordiskView company profile and Eli LillyView company profile each presented early data at the Aging Research & Drug Discovery (ARDD) conference at Harvard suggesting that their GLP-1 receptor (search)Search target agonists may slow molecular measures of biological aging, the first clinical readouts tying the drug class to aging clocks.
